HYL.BR BRU
Hyloris Pharmaceuticals S.A.
1W: -5.6%
1M: -6.5%
3M: -4.1%
YTD: -43.4%
1Y: -35.4%
3Y: -64.0%
5Y: -68.4%
€4.20 ($4.69)
-0.05 (-1.18%)
Weekly Expected Move ±5.8%
€4
€4
€4
€4
€5
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$7M
-28.2% ▼
5Y CAGR: +110.4%
Gross Profit
$6M
-39.8% ▼
5Y CAGR: +187.7%
Operating Income
-$9M
-30.9% ▼
Net Income
-$6M
+0.1% ▲
EPS (Diluted)
$-0.23
-4.5% ▼
EBITDA
-$8M
-73.6% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3M | $3M | $2M | $10M | $7M |
| YoY Growth | +1669.1% | -4.7% | -29.3% | +381.2% | -28.2% |
| Cost of Revenue | $107K | $94K | $93K | $227K | $1M |
| Gross Profit | $3M | $3M | $2M | $10M | $6M |
| Gross Margin | 96.5% | 96.8% | 95.5% | 97.7% | 82.0% |
| R&D Expenses | $5M | $10M | $14M | $10M | $11M |
| SG&A Expenses | $3M | $4M | $6M | $6M | $4M |
| Operating Expenses | $13M | $13M | $18M | $17M | $15M |
| Operating Income | -$5M | -$12M | -$16M | -$7M | -$9M |
| Operating Margin | -159.7% | -394.4% | -766.3% | -71.0% | -129.5% |
| Interest Expense | $583K | $285K | $100K | $135K | $739K |
| Income Before Tax | -$11M | -$12M | -$15M | -$6M | -$7M |
| Tax Expense | $297K | $4K | -$593K | -$81K | -$374K |
| Net Income | -$12M | -$12M | -$15M | -$6M | -$6M |
| Net Margin | -374.0% | -403.5% | -736.9% | -63.2% | -87.9% |
| EPS (Diluted) | $-0.45 | $-0.44 | $-0.55 | $-0.22 | $-0.23 |
| EBITDA | -$11M | -$11M | -$15M | -$5M | -$8M |
| Shares Outstanding | 26M | 27M | 28M | 29M | 28M |